CN115317543A - Traditional Chinese medicine composition for treating liver cancer cachexia and application thereof - Google Patents
Traditional Chinese medicine composition for treating liver cancer cachexia and application thereof Download PDFInfo
- Publication number
- CN115317543A CN115317543A CN202211109828.1A CN202211109828A CN115317543A CN 115317543 A CN115317543 A CN 115317543A CN 202211109828 A CN202211109828 A CN 202211109828A CN 115317543 A CN115317543 A CN 115317543A
- Authority
- CN
- China
- Prior art keywords
- parts
- group
- cancer cachexia
- liver cancer
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 206010006895 Cachexia Diseases 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 23
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 23
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 29
- 244000298697 Actinidia deliciosa Species 0.000 claims abstract description 25
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims abstract description 25
- 241000893536 Epimedium Species 0.000 claims abstract description 23
- 244000197580 Poria cocos Species 0.000 claims abstract description 23
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 23
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 23
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 23
- 235000018905 epimedium Nutrition 0.000 claims abstract description 23
- 241000132012 Atractylodes Species 0.000 claims abstract description 22
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 21
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 4
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 3
- 229940079593 drug Drugs 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 14
- 208000022531 anorexia Diseases 0.000 abstract description 6
- 206010061428 decreased appetite Diseases 0.000 abstract description 6
- 230000007812 deficiency Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000009469 supplementation Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 23
- 239000008194 pharmaceutical composition Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 102000004420 Creatine Kinase Human genes 0.000 description 10
- 108010042126 Creatine kinase Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 230000001612 cachectic effect Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 244000059800 Amomum compactum Species 0.000 description 1
- 235000016426 Amomum compactum Nutrition 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 206010051986 Pneumatosis Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating liver cancer cachexia, which is prepared from the following raw material medicines by weight: 16-24 parts of kiwi fruit juice, 6-14 parts of salvia miltiorrhiza, 3-7 parts of bighead atractylodes rhizome, 2-6 parts of epimedium herb, 2-6 parts of poria cocos, 1-4 parts of radix bupleuri, 3-7 parts of schisandra chinensis and 3-7 parts of radix pseudostellariae. The invention also provides application of the traditional Chinese medicine composition in preparing a medicine for treating liver cancer cachexia. The invention has the advantages of exactly matching the difficulty of treating cancer cachexia, namely 'deficiency and no supplementation', improving the anorexia and the weakness of patients with the liver cancer cachexia, having no toxic or side effect and having wide clinical application prospect in treating the liver cancer cachexia.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating liver cancer cachexia and application thereof.
Background
Cachexia is one of the leading causes of death in cancer patients, and according to international clinical epidemiological studies, it has been shown that approximately 40% -80% of cancer patients develop cachexia in late stages, leading to death in patients. The clinical manifestations of cachexia are a progressive decrease in body mass. The main reason why patients with liver cancer are prone to cachexia is that liver cancer cells easily secrete a plurality of inflammatory factors, and the inflammatory factors are released into blood in large quantities. Meanwhile, the liver is the central organ for regulating the metabolism of the organism. At present, the main clinical means for cancer treatment include chemotherapy, radiotherapy, targeted drug application and the like, and the aim of delaying the progress of the disease of a patient and prolonging the survival period of the patient is achieved by inhibiting or killing cancer cells. However, these approaches are not effective in delaying the onset of cachexia.
Cancer cachexia is often accompanied by anorexia, and compared with western medicines, the traditional Chinese medicine has the advantages of integral regulation, less side effects and definite curative effect in the aspect of treating cancer anorexia. There is no name of cancer cachexia in traditional Chinese medicine, but there are many symptoms described similar to cachexia, and the 'Su Wen & Yu Ji Zhencang Lun' has the symptoms of 'withered bones, big flesh collapse, fullness in chest, dyspnea with inconvenience, pneumatosis, death in six months' which are very similar to late-stage liver cancer with cachexia. The traditional Chinese medicine considers that the pathogenesis cause of cancer cachexia is as follows: deficiency-middle-excess refers to the coexistence of qi and blood deficiency of the whole body and excess pathogens of the zang-fu organs and local tumors, one of the main key pathogenesis is the serious decline of the biochemical function of acquired qi and blood, the source of tonifying the acquired biochemical is one of the important treatment principles for treating the disease, and the chronic disease involving the kidney and the deficiency of the spleen and kidney are also the important pathogenesis of the disease. Aiming at the symptoms of cancer cachexia and anorexia clinically, the traditional Chinese medicine mainly takes the effects of tonifying qi and nourishing yin, activating spleen and invigorating stomach to promote digestion, tonifying spleen and stomach and the like as main treatment rules, and has better clinical effects of regulating qi or activating blood and dissolving stasis and the like. How to tonify and promote the recovery of cancer cachexia, and 'deficiency without tonification' is the bottleneck of clinical treatment.
Another previous patent CN102772732a of the present applicant discloses a pharmaceutical composition for treating chronic liver disease, which is prepared from the following raw materials in parts by weight: 20-60 parts of kiwi fruit juice, 10-30 parts of salvia miltiorrhiza, 5-15 parts of bighead atractylodes rhizome, 4-12 parts of epimedium herb, 4-12 parts of poria cocos, 2-6 parts of radix bupleuri, 5-15 parts of schisandra chinensis, 1.5-4.5 parts of round cardamom, 2.5-7.5 parts of dried orange peel and 5-15 parts of radix pseudostellariae. Meanwhile, the subject group of the inventor prepares the liver-protecting prescription 919 granules based on the pharmaceutical composition in the application, and the prescription is a traditional Chinese medicine compound preparation formed by combining clinical personal experience with folk proved recipes. Clinical and basic research for more than 30 years proves that the liver-protecting tea has exact functions of protecting liver, reducing enzyme, resisting hepatitis B virus, resisting hepatic steatosis and resisting hepatic fibrosis. According to the tonifying and eliminating two methods in the eight methods of the traditional Chinese medicine, the compatibility of the liver-protecting prescription 919 granules tonifies the liver while tonifying the liver, promotes blood circulation and regulates qi, achieves the effect of tonifying, can improve the anorexia and the weakness of cancer cachexia patients, and has no toxic or side effect. The formula of the formula exactly accords with the difficulty of treating the liver cancer cachexia, namely deficiency and invigoration, and the formula for treating the liver cancer cachexia has wide clinical application prospect.
There is no report on the use of the present invention for treating liver cancer cachexia.
Disclosure of Invention
The first purpose of the present invention is to provide a Chinese medicine composition for treating liver cancer cachexia, which aims at the defects in the prior art.
The second purpose of the invention is to provide the application of the pharmaceutical composition for treating the liver cancer cachexia.
In order to realize the first purpose, the invention adopts the technical scheme that:
a traditional Chinese medicine composition for treating liver cancer cachexia is prepared from the following raw material medicines in parts by weight:
16-24 parts of kiwi fruit juice, 6-14 parts of salvia miltiorrhiza, 3-7 parts of bighead atractylodes rhizome, 2-6 parts of epimedium herb, 2-6 parts of poria cocos, 1-4 parts of radix bupleuri, 3-7 parts of schisandra chinensis and 3-7 parts of radix pseudostellariae.
As a preferred example, the traditional Chinese medicine composition is prepared from the following raw medicines in parts by weight:
18-22 parts of kiwi fruit juice, 8-12 parts of salvia miltiorrhiza, 4-6 parts of bighead atractylodes rhizome, 3-5 parts of epimedium herb, 3-5 parts of poria cocos, 1-3 parts of radix bupleuri, 4-6 parts of schisandra chinensis and 4-6 parts of radix pseudostellariae.
More preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight:
20 parts of kiwi fruit juice, 10 parts of salvia miltiorrhiza, 5 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 4 parts of tuckahoe, 2 parts of radix bupleuri, 5 parts of schisandra chinensis and 5 parts of radix pseudostellariae.
The preparation method of the pharmaceutical composition comprises the following steps:
(a) Placing fructus Schisandrae chinensis, bupleuri radix, and Atractylodis rhizoma into a distillation pot, adding three times of water, distilling to obtain distilled volatile oil solution, and sealing and storing;
(b) Adding water into the distilled dregs, decocting for one hour, standing for ten hours, filtering to obtain juice, collecting and concentrating;
(c) Placing Saviae Miltiorrhizae radix, radix Pseudostellariae, herba Epimedii, poria, and the four materials into a decocting pot, decocting with water twice, boiling for one hour, naturally cooling, filtering to obtain juice, mixing the decoctions, standing for six hours, filtering to obtain juice, collecting, and mixing;
(d) Mixing the filtrate obtained in the step (b) and the filtrate obtained in the step (c), and concentrating the mixture by adopting a low-temperature reduced pressure concentration method until the specific gravity is 1:1, adding 20/10 of the filtrate and kiwi fruit juice, adding the volatile oil solution obtained in the step (a) and distilled water, mixing, fully stirring to obtain a thick extract, and then granulating, drying and finishing.
As a preferred example, the dosage form of the traditional Chinese medicine composition is granules.
In order to achieve the second object, the invention adopts the technical scheme that:
the application of the traditional Chinese medicine composition in preparing a medicine for treating liver cancer cachexia.
The compatibility relationship of the traditional Chinese medicine composition is as follows:
in the prescription, the kiwi fruit is used as a monarch drug, and the Chinese herbal compendium says that the kiwi fruit is sour, sweet, cold and nontoxic, enters liver, spleen, kidney, heart and lung channels, stops sudden thirst, and relieves restlessness and heat. According to the traditional Chinese medicine theory of 'seeing liver disease, knowing liver and transmitting spleen, and when spleen is firstly performed', ginseng, bighead atractylodes rhizome, poria cocos, spleen strengthening and stomach are used as ministerial drugs, liver spleen disease affects kidney yin and yang, epimedium herb regulation yin and yang is used as an adjuvant drug, liver yin and yang are used, salvia miltiorrhiza one-taste is used for four-drug decoction, blood is enriched and blood is activated, and the radix bupleuri and schisandra chinensis one-powder one-astringing are used as guiding drugs. The prescription combines the methods of nourishing the liver, strengthening the spleen, nourishing the kidney, harmonizing the stomach, regulating the flow of qi, invigorating the blood circulation and the like in one furnace to form a compound prescription.
Detailed Description
The present invention will be further described with reference to the following embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes and modifications can be made by those skilled in the art after reading the disclosure of the present invention, and equivalents fall within the scope of the appended claims.
EXAMPLE 1 pharmaceutical composition (I)
20 parts of kiwi fruit juice, 10 parts of salvia miltiorrhiza, 5 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 4 parts of poria cocos, 2 parts of radix bupleuri, 5 parts of schisandra chinensis and 5 parts of radix pseudostellariae.
EXAMPLE 2 pharmaceutical composition (II)
20 parts of kiwi fruit juice, 8 parts of salvia miltiorrhiza, 6 parts of bighead atractylodes rhizome, 2 parts of epimedium herb, 6 parts of poria cocos, 2 parts of radix bupleuri, 4 parts of schisandra chinensis and 6 parts of radix pseudostellariae.
EXAMPLE 3 pharmaceutical composition (III)
18 parts of kiwi fruit juice, 12 parts of salvia miltiorrhiza, 3 parts of bighead atractylodes rhizome, 6 parts of epimedium herb, 4 parts of poria cocos, 1 part of radix bupleuri, 6 parts of schisandra chinensis and 3 parts of radix pseudostellariae.
EXAMPLE 4 pharmaceutical composition (IV)
22 parts of kiwi fruit juice, 6 parts of salvia miltiorrhiza, 7 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 3 parts of poria cocos, 3 parts of radix bupleuri, 3 parts of schisandra chinensis and 7 parts of radix pseudostellariae.
EXAMPLE 5 composition (V)
16 parts of kiwi fruit juice, 14 parts of salvia miltiorrhiza, 5 parts of bighead atractylodes rhizome, 3 parts of epimedium herb, 5 parts of poria cocos, 1 part of radix bupleuri, 7 parts of schisandra chinensis and 5 parts of radix pseudostellariae.
EXAMPLE 6 pharmaceutical composition (VI)
24 parts of kiwi fruit juice, 10 parts of salvia miltiorrhiza, 4 parts of bighead atractylodes rhizome, 5 parts of epimedium herb, 2 parts of poria cocos, 4 parts of radix bupleuri, 5 parts of schisandra chinensis and 4 parts of radix pseudostellariae.
EXAMPLE 7 pharmaceutical composition (VII) for treatment of liver cancer cachexia
20 parts of kiwi fruit juice, 12 parts of salvia miltiorrhiza, 3 parts of bighead atractylodes rhizome, 6 parts of epimedium herb, 4 parts of poria cocos, 1 part of radix bupleuri, 6 parts of schisandra chinensis and 3 parts of radix pseudostellariae.
EXAMPLE 8 pharmaceutical composition (eight)
18 parts of kiwi fruit juice, 6 parts of salvia miltiorrhiza, 7 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 3 parts of poria cocos, 3 parts of radix bupleuri, 3 parts of schisandra chinensis and 7 parts of radix pseudostellariae.
EXAMPLE 9 pharmaceutical composition (nine)
22 parts of kiwi fruit juice, 14 parts of salvia miltiorrhiza, 5 parts of bighead atractylodes rhizome, 3 parts of epimedium herb, 5 parts of poria cocos, 1 part of radix bupleuri, 7 parts of schisandra chinensis and 5 parts of radix pseudostellariae.
EXAMPLE 10 pharmaceutical composition (Ten)
16 parts of kiwi fruit juice, 10 parts of salvia miltiorrhiza, 4 parts of bighead atractylodes rhizome, 5 parts of epimedium herb, 2 parts of poria cocos, 4 parts of radix bupleuri, 5 parts of schisandra chinensis and 4 parts of radix pseudostellariae.
EXAMPLE 11 pharmaceutical composition (eleven)
24 parts of kiwi fruit juice, 8 parts of salvia miltiorrhiza, 6 parts of bighead atractylodes rhizome, 2 parts of epimedium herb, 2 parts of poria cocos, 2 parts of radix bupleuri, 4 parts of schisandra chinensis and 6 parts of radix pseudostellariae.
EXAMPLE 12 preparation of pharmaceutical composition
(a) Placing fructus Schisandrae chinensis, bupleuri radix, and Atractylodis rhizoma into a distillation pot, adding three times of water, distilling, collecting the volatile oil solution, sealing, and storing. And adding water into the distilled dregs, decocting for one hour, standing for ten hours, filtering to obtain juice, and collecting and concentrating.
(b) Putting the salvia miltiorrhiza, the radix pseudostellariae, the epimedium herb, the poria cocos and the four medicines into a decocting pot, adding water to boil twice, keeping boiling for one hour, naturally cooling, filtering to obtain juice, combining the two decoctions, standing for six hours, filtering to obtain the juice, collecting and packaging to be mixed for preparation.
(c) Mixing the filtrate obtained in the step (b) and the filtrate obtained in the step (c), and concentrating the mixture by adopting a low-temperature reduced pressure concentration method until the specific gravity is 1:1, mixing the filtrate and 20/10 of kiwi fruit juice, adding the volatile oil solution obtained in the step (a) and distilled water, fully stirring to obtain a thick extract, and then granulating, drying and finishing.
Example 13 animal experiments
1 Material
1.1 Experimental animals
90 male and female BALB/c mice 7 weeks old were purchased from Shanghai Ji Hui laboratory animal feeding company [ SCXK (Shanghai) 2017-0012], weighed 18-28g, and placed in animal housing (SPF grade) of public health clinic center in Shanghai city. One cage per 5 mice was housed in plastic squirrel cages (300X 200X 120 mm) lined with wood chips. The room was kept under standard conditions of constant temperature (23 ± 3 ℃), constant humidity (50% ± 10%), illumination for 12 hours (8. Except for the time of restraint, sterile food and water were freely available to all mice throughout the experiment.
1.2 instruments and reagents
1.2.1 reagents
Propranolol hydrochloride (Changzhou Yabang pharmaceutical Co., ltd., content: 99.4%); 9.4% Fetal Bovine Serum (FBS), pancreatin, streptomycin (Gibco, USA); modified RPMI 1640 medium (Hyclone, USA); a coomassie protein determination kit and a plasma Creatine Kinase (CK) test kit (Nanjing institute of bioengineering); proinflammatory factor interleukin-1 beta (1L-beta), interleukin-6 (1L-6), tumor necrosis factor-alpha (TNF-alpha) enzyme-linked immunosorbent assay (ELISA) kit (Shanghai Eikei biological products, inc.).
1.2.2 instruments
Eclipse Ties type inverted microscope (japan nikon corporation); a SUNRISE type microplate reader (Tecan, switzerland); AU2700 model fully automatic biochemical analyzer (Beckman Coulter, USA); model CM 3050 frozen microtome (Leica, germany); galaxy171R cell incubator, 5430R desk-top cryocentrifuge (Eppendorf, germany).
2 protocol for the experiment
2.1 animal Molding
The hepatoma cell line HepG2 was recovered and treated with cell culture medium (modified RPMI 1640 medium, 10% FBS, 100mg/L-streptomycin and 1/10% 5 U/L-penicillin) adjusted to a density of 1X 10 5 seed/mL, inoculated in a 100mm petri dish, subjected to 37 ℃ 5% CO 2 Culturing in an incubator. When the cells grow and become fullAdding 0.05% pancreatin for digestion, collecting cells, and preparing into 1 × 10 with physiological saline 7 one/mL, 60 BALB/C inbred mice were injected into the subcutaneous area under the axilla of the right forelimb, and then the mice were further bred. After 4 weeks of rearing, animals with tumor growth were selected, anesthetized and sterilized, and the tumor tissue developed was taken out. Shearing the tumor to 1.0mm at 4 deg.C 3 Enduring small tissue masses on the left and right. After the tissue pieces were washed clean with 0.01% Phosphate Buffered Saline (PBS), they were re-implanted into the axilla of the right anterior limb of BALB/C inbred mice. When the mice obviously get lean, have anorexia, weakness and failure and the physical quality is reduced to have obvious difference with the normal group, the mice enter a cachexia state, and the model preparation is proved to be successful. After 28 days, when the tumor appearance grows and the mouse body mass begins to decrease, the grouping administration is started.
2.2 grouping and administration
Randomly selecting 60 mice successfully molded, dividing the mice into 6 groups, each group comprises 10 mice, each half of the mice is a first group of the invention, a second group of the invention, a first control group, a second control group, a model group and a western medicine group, selecting 10 mice without molding as blank groups, and continuously administering for 10 days according to the following mode:
the invention comprises the following components: the raw materials were weighed according to the weight parts described in example 1, and the drug was prepared according to example 12 by drenching a granular drug solution (dissolved in distilled water, 1.5 g/mL) of 20mL/kg daily.
The invention has the following group two: the raw materials were weighed according to the weight parts described in example 2, and the drug was prepared according to example 12 by drenching a granular drug solution (dissolved in distilled water, 1.5 g/mL) of 20mL/kg daily.
Control group one: weighing 20 parts of kiwi fruit juice, 10 parts of salvia miltiorrhiza, 5 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 4 parts of poria cocos, 2 parts of radix bupleuri, 5 parts of schisandra chinensis, 1.5 parts of cardamom, 2.5 parts of dried orange peel and 5 parts of radix pseudostellariae according to the weight part ratio, preparing the medicine according to the embodiment 12, and filling 20mL/kg of the particle medicine solution (dissolved in distilled water and 1.5 g/mL) every day.
Control group two: weighing 20 parts of kiwi fruit juice, 10 parts of salvia miltiorrhiza, 5 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 4 parts of tuckahoe, 2 parts of radix bupleuri, 5 parts of dark plum fruit and 5 parts of American ginseng according to the weight part ratio. The drug was prepared as in example 12 by daily drenching of 20mL/kg of a particulate drug solution (1.5 g/mL in distilled water).
Western medicine group: propranolol is administered at a dose of 3mg/kg per day.
Model group: the stomach is irrigated with 20mL/kg of physiological saline every day.
Blank group: the stomach is irrigated with 20mL/kg of physiological saline every day.
2.3 detection of indicators
2.3.1 evaluation of mouse body quality
The body mass of the mice after modeling is measured, and the state of the mice under cachexia is accurately reflected.
2.3.2 ELISA for detecting mouse plasma CK and proinflammatory factor level
Each group of mice was anesthetized with sodium pentobarbital (40 mg/kg), the abdominal aorta was bled, heparin was anticoagulated, the supernatant plasma was transferred to a new 1.5mL centrifuge tube by centrifugation at 3000r/min for 10min, and stored at-20 ℃. The levels of CK and 1L-1 beta, 1L-6, TNF-alpha were determined separately using ELISA kits according to the instructions.
3 statistical analysis
Data processing was performed using SPSS 23.0 statistical software, and the results of the experiments were represented as mean. + -. Standard error (X. + -. SEM) for comparison of differences between different groups using One-way ANOVAwith T-test for statistical analysis, with P <0.05 being statistically significant.
4 results
4.1 Effect on the quality of mice with liver cancer cachexia
Compared with the blank group, the constitution and the quality of the mice in the cachexia model group are obviously reduced (p is less than 0.001); compared with a model group, the group of the invention and a western medicine group control group can obviously delay the reduction of the constitution and the quality of the mice with the liver cancer cachexia (p is less than 0.05); wherein the effects of the first invention group and the second invention group are better than those of the first control group and the second control group (p is less than 0.05); the group I of the invention has no obvious difference from the western medicine group, and is shown in table 1.
TABLE 1 influence of the Chinese medicinal composition on the body quality of mice with liver cancer cachexia: (
n＝70)
| Group of | n (example) | Mass/g |
| The invention is combined into | 10 | 24.19±1.96 2,3) |
| Invention group two | 10 | 23.09±2.55 2,3) |
| Control group one | 10 | 22.39±1.881 2) |
| Control group two | 10 | 22.61±1.89 2) |
| Western medicine group | 10 | 24.08±2.10 2) |
| Model set | 10 | 21.95±2.19 1) |
| Blank group | 10 | 25.51±1.14 |
Note: comparison with blank group 1) (p<0.001 ); comparison with model group 2) (p<0.05 ); comparing with control group 3) (p<0.05)
4.2 Effect on plasma CK levels of mouse skeletal muscle catabolite products
Compared with a blank group, the plasma creatine kinase level of the cachexia model group is obviously increased (P < 0.01); compared with the model group, the plasma creatine kinase level of the invention group, the western medicine group and the control group is obviously reduced (P < 0.05); compared with a control group, the blood creatine kinase level of the group is further reduced (P < 0.01), which indicates that the muscle degradation degree is obviously reduced; the inhibition level of the first group of the invention is obviously stronger than that of the second group of the invention (P < 0.05); the inhibition level of the first medicament has no obvious difference with that of western medicaments, and is shown in a table 2.
TABLE 2 Effect of Chinese medicinal compositions on creatine kinase levels in plasma of cachectic mice: (
n＝70)
| Group of | n (example) | CK/UL -1 |
| The invention is combined into | 10 | 69.31±12.28 2,3,4) |
| Invention group two | 10 | 75.73±11.05 2.3) |
| Control group one | 10 | 87.12±9.66 2) |
| Control group two | 10 | 83.55±14.14 2) |
| Western medicine group | 10 | 72.31±11.30 2) |
| Model set | 10 | 137.29±21.42 1) |
| Blank group | 10 | 66.21±11.72 |
Note: comparison with blank group 1) (p<0.01 ); comparison with model group 2) (p<0.05 ); comparing with control group 3) (p<0.01 ); comparison with group two of the present invention 4) (p<0.05)
4.3 inhibition of the secretion level of 1L-1 beta, 1L-6, TNF-alpha in the plasma of cachectic mice by the Chinese medicinal composition
Compared with a blank group, the 1L-1 beta, 1L-6, TNF-alpha level in the plasma of mice in a cachexia model group is obviously increased (P < 0.001); compared with the model group, the levels of 1L-1 beta, 1L-6 TNF-alpha of the invention group, the western medicine group and the control group are obviously reduced (P is less than 0.05); compared with a control group, the group of the invention has obvious inhibition effect (P < 0.05); wherein the level of 1L-1 beta in the first group of the invention is significantly lower than that in the western group (P < 0.05); the invention is significantly lower than the control group (P < 0.05), (P < 0.01); wherein 1L-6 of the first group of the invention is significantly lower than that of the western medicine group and the second group of the invention (P < 0.05); and TNF- α was significantly lower in group one than in group two (P < 0.05), see table 3.
TABLE 3 Effect of Chinese medicinal compositions on 1L-1 beta, 1L-6, TNF-alpha levels in plasma of cachectic mice: (
n＝70)
| Group of | n (example) | 1L-1β | 1L-6 | TNF-α |
| The invention is combined into | 10 | 66.43±17.28 2,3,5) | 618.92±128.59 2,4,5,6) | 644.18±144.04 2,3,6) |
| Invention group two | 10 | 72.41±12.42 2,3) | 738.88±47.04 2,3) | 748.18±93.09 2,3) |
| Control group one | 10 | 84.51±10.15 2) | 845.99±86.45 2) | 849.84±104.73 2) |
| Control group two | 10 | 81.87±13.54 2) | 822.67±130.13 2) | 843.70±192.10 2) |
| Western medicine group | 10 | 79.88±9.44 2) | 760.89±115.63 2) | 700.53±87.08 2) |
| Model set | 10 | 107.89±15.93 1) | 1007.24±193.86 1) | 979.28±133.70 1) |
| Blank group | 10 | 55.21±11.85 | 548.93±81.97 | 494.18±93.04 |
Note: comparison with blank group 1) (p<0.001 ); comparison with model group 2) (p<0.05 ); comparing with control group 3) (p<0.05)， 4) p<0.001 ); compared with the western medicine group 5) (p<0.05 ); comparison with group two of the present invention 6) (p<0.05)
In conclusion, the medicines of the invention, the western medicine group and the control group can inhibit the cachexia process of a mouse cachexia model induced by a human hepatoma cell line Hep G2 to different degrees, the medicine inhibition effect of the invention group is better than that of the control group, and the effect of the invention group is the most prominent overall.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.
Claims (5)
1. A traditional Chinese medicine composition for treating liver cancer cachexia is characterized by being prepared from the following raw materials in parts by weight: 16-24 parts of kiwi fruit juice, 6-14 parts of salvia miltiorrhiza, 3-7 parts of bighead atractylodes rhizome, 2-6 parts of epimedium herb, 2-6 parts of poria cocos, 1-4 parts of radix bupleuri, 3-7 parts of schisandra chinensis and 3-7 parts of radix pseudostellariae.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 18-22 parts of kiwi fruit juice, 8-12 parts of salvia miltiorrhiza, 4-6 parts of bighead atractylodes rhizome, 3-5 parts of epimedium herb, 3-5 parts of poria cocos, 1-3 parts of radix bupleuri, 4-6 parts of schisandra chinensis and 4-6 parts of radix pseudostellariae.
3. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 20 parts of kiwi fruit juice, 10 parts of salvia miltiorrhiza, 5 parts of bighead atractylodes rhizome, 4 parts of epimedium herb, 4 parts of tuckahoe, 2 parts of radix bupleuri, 5 parts of schisandra chinensis and 5 parts of radix pseudostellariae.
4. The Chinese medicinal composition of claim 1, wherein the Chinese medicinal composition is in the form of granules.
5. Use of the Chinese medicinal composition of any one of claims 1-3 in the preparation of a medicament for treating liver cancer cachexia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211109828.1A CN115317543B (en) | 2022-09-13 | 2022-09-13 | Traditional Chinese medicine composition for treating liver cancer cachexia and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211109828.1A CN115317543B (en) | 2022-09-13 | 2022-09-13 | Traditional Chinese medicine composition for treating liver cancer cachexia and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115317543A true CN115317543A (en) | 2022-11-11 |
| CN115317543B CN115317543B (en) | 2023-05-23 |
Family
ID=83929310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211109828.1A Active CN115317543B (en) | 2022-09-13 | 2022-09-13 | Traditional Chinese medicine composition for treating liver cancer cachexia and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115317543B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1064215A (en) * | 1991-02-13 | 1992-09-09 | 吴卫清 | The preparation method of Chinese medicine fruit juice dosage form |
| CN101756223A (en) * | 2008-11-21 | 2010-06-30 | 刘兴廉 | Health-care nutrient rice dumpling |
| DE102011008017A1 (en) * | 2011-01-06 | 2012-07-12 | Johannes F. Coy | soft drink |
| CN102772732A (en) * | 2012-08-17 | 2012-11-14 | 复旦大学附属金山医院 | Medicine composition for treating chronic liver disease |
| CN105213993A (en) * | 2015-11-04 | 2016-01-06 | 季旭明 | One improves cachectic Chinese medicine composition of intestinal cancer and preparation method thereof |
| US20160067202A1 (en) * | 2013-04-22 | 2016-03-10 | Smartfish As | Use of a composition comprising fish oil and juice for the treatment and/or post treatment of cancer |
| CN107080257A (en) * | 2017-06-20 | 2017-08-22 | 哈尔滨工业大学 | A kind of preparation of liver protecting raspberry lozenge |
| CN108096299A (en) * | 2018-01-24 | 2018-06-01 | 郑州大学 | Chinese gooseberry seed active site extraction separation method and its application |
| CN114404538A (en) * | 2022-03-01 | 2022-04-29 | 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) | Traditional Chinese medicine composition for treating gouty arthritis and application thereof |
-
2022
- 2022-09-13 CN CN202211109828.1A patent/CN115317543B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1064215A (en) * | 1991-02-13 | 1992-09-09 | 吴卫清 | The preparation method of Chinese medicine fruit juice dosage form |
| CN101756223A (en) * | 2008-11-21 | 2010-06-30 | 刘兴廉 | Health-care nutrient rice dumpling |
| DE102011008017A1 (en) * | 2011-01-06 | 2012-07-12 | Johannes F. Coy | soft drink |
| CN102772732A (en) * | 2012-08-17 | 2012-11-14 | 复旦大学附属金山医院 | Medicine composition for treating chronic liver disease |
| US20160067202A1 (en) * | 2013-04-22 | 2016-03-10 | Smartfish As | Use of a composition comprising fish oil and juice for the treatment and/or post treatment of cancer |
| CN105213993A (en) * | 2015-11-04 | 2016-01-06 | 季旭明 | One improves cachectic Chinese medicine composition of intestinal cancer and preparation method thereof |
| CN107080257A (en) * | 2017-06-20 | 2017-08-22 | 哈尔滨工业大学 | A kind of preparation of liver protecting raspberry lozenge |
| CN108096299A (en) * | 2018-01-24 | 2018-06-01 | 郑州大学 | Chinese gooseberry seed active site extraction separation method and its application |
| CN114404538A (en) * | 2022-03-01 | 2022-04-29 | 复旦大学附属金山医院(上海市金山区眼病防治所、上海市金山区核化伤害应急救治中心) | Traditional Chinese medicine composition for treating gouty arthritis and application thereof |
Non-Patent Citations (7)
| Title |
|---|
| JING-WEI XING，等: "919 syrup inhibits ROS-mediated leptin-induced anorexia by activating PPARγ and improves gut flora abnormalities", BIOMEDICINE & PHARMACOTHERAPY * |
| XIN-YUN TIAN，等: "919 Syrup Alleviates Postpartum Depression by Modulating the Structure and Metabolism of Gut Microbes and Affecting the Function of the Hippocampal GABA/Glutamate System", FRONT CELL INFECT MICROBIOL * |
| 倪美鑫，等: "补康灵对Lewis肺癌小鼠癌性恶病质的改善作用研究", 中国药房 * |
| 孙镝，等: "黄萱益肝散治疗慢性乙型肝炎疗效观察", 药品评价 * |
| 徐月妹，等: "919糖浆对肝郁气滞血瘀证模型大鼠脑胃ghrelin通路的影响", 上海中医药杂志 * |
| 徐玲，等: "四君子汤对癌性恶病质小鼠血清细胞因子的影响", 中华中医药学刊 * |
| 高鹏飞，等: "919糖浆护肝的实验研究", 上海中医药杂志 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115317543B (en) | 2023-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103211974B (en) | Medicinal liquor for improving immunity and application thereof | |
| CN110075216A (en) | It is a kind of with the food compositions and preparation method thereof, preparation and the application that assist reducing blood lipid, hepatoprotective effect of losing weight | |
| CN104758556B (en) | A kind of compound preparation and preparation method thereof of anti-Heat stress | |
| CN115120689B (en) | Application of Xinlikangfang preparation in drug preparation | |
| CN111110733B (en) | Traditional Chinese medicine composition for treating senile gouty arthritis and preparation method and application thereof | |
| CN111166837B (en) | Traditional Chinese medicine composition for treating colorectal cancer and application thereof | |
| CN111557968A (en) | A kind of traditional Chinese medicine compound composition and application with regulating immune function | |
| WO2021142920A1 (en) | Traditional chinese medicine composition for treating lung cancer, and preparation and use thereof | |
| CN102389559B (en) | A kind of traditional Chinese medicine composition and its application as radiotherapy sensitizer | |
| CN112807383A (en) | Compound lucid ganoderma composition for improving senile dementia and preparation method thereof | |
| CN104095992B (en) | A kind of composition of energy permanent tooth strengthening the bones and muscles and anti-aging of being healthy and strong and preparation method and application | |
| CN115317543B (en) | Traditional Chinese medicine composition for treating liver cancer cachexia and application thereof | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN101869603A (en) | Traditional Chinese medicine composition for protecting liver and preventing liver damage and preparation method thereof | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN103169838B (en) | Medicine for treating hepatitis B | |
| CN103191267B (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN103705731B (en) | A kind of Chinese medicine composition for the treatment of chronic alcoholic toxic liver disease | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN118806832B (en) | Traditional Chinese medicine composition for advanced primary liver cancer and application thereof | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN109200108B (en) | Traditional Chinese medicine composition for treating depression and preparation method and application thereof | |
| CN109620911B (en) | Traditional Chinese medicine composition capable of improving neutropenia after chemotherapy and application thereof | |
| CN110123871B (en) | Traditional Chinese medicine composition preparation for improving leucocyte and expelling toxin and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |